These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8289884)

  • 1. Mass ligand-binding screening strategies for identification of leads for new drug discovery.
    Burch RM
    NIDA Res Monogr; 1993; 134():37-45. PubMed ID: 8289884
    [No Abstract]   [Full Text] [Related]  

  • 2. Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening.
    Tanrikulu Y; Schneider G
    Nat Rev Drug Discov; 2008 Aug; 7(8):667-77. PubMed ID: 18636071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interrogating 7TM receptors: does texture in the question yield greater texture in the answer?
    Kenakin T
    J Recept Signal Transduct Res; 2009; 29(3-4):132-9. PubMed ID: 19580378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of ESI-MS in drug discovery: interrogation of noncovalent complexes.
    Hofstadler SA; Sannes-Lowery KA
    Nat Rev Drug Discov; 2006 Jul; 5(7):585-95. PubMed ID: 16816839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of constitutively active receptors for drug discovery at the G protein-coupled receptor gene pool.
    Behan DP; Chalmers DT
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):548-60. PubMed ID: 12825451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand discovery using small molecule microarrays.
    He XG; Gerona-Navarro G; Jaffrey SR
    J Pharmacol Exp Ther; 2005 Apr; 313(1):1-7. PubMed ID: 15537823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontal affinity chromatography with MS detection (FAC-MS) in drug discovery.
    Slon-Usakiewicz JJ; Ng W; Dai JR; Pasternak A; Redden PR
    Drug Discov Today; 2005 Mar; 10(6):409-16. PubMed ID: 15808820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand binding efficiency: trends, physical basis, and implications.
    Reynolds CH; Tounge BA; Bembenek SD
    J Med Chem; 2008 Apr; 51(8):2432-8. PubMed ID: 18380424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virtual screening strategies in drug discovery.
    McInnes C
    Curr Opin Chem Biol; 2007 Oct; 11(5):494-502. PubMed ID: 17936059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation.
    Vauquelin G; Szczuka A
    Neurochem Int; 2007 Oct; 51(5):254-60. PubMed ID: 17606314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Affinity selection-mass spectrometry screening techniques for small molecule drug discovery.
    Annis DA; Nickbarg E; Yang X; Ziebell MR; Whitehurst CE
    Curr Opin Chem Biol; 2007 Oct; 11(5):518-26. PubMed ID: 17931956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-based ligand discovery.
    Fischer M; Hubbard RE
    Mol Interv; 2009 Feb; 9(1):22-30. PubMed ID: 19299661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear hormone receptor assays for drug discovery.
    Rosen J; Marschke K; Rungta D
    Curr Opin Drug Discov Devel; 2003 Mar; 6(2):224-30. PubMed ID: 12669458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The modular approach to ligand discovery.
    Karan C; Tallarico JA
    Chem Biol; 2004 Mar; 11(3):292-3. PubMed ID: 15123257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A mathematical description of ligand-receptor interaction and computer identification of its parameters].
    Qian GZ; Yang YL
    Zhongguo Yao Li Xue Bao; 1987 Jul; 8(4):297-300. PubMed ID: 3445770
    [No Abstract]   [Full Text] [Related]  

  • 16. Screening the receptorome: an efficient approach for drug discovery and target validation.
    Strachan RT; Ferrara G; Roth BL
    Drug Discov Today; 2006 Aug; 11(15-16):708-16. PubMed ID: 16846798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The many roles of computation in drug discovery.
    Jorgensen WL
    Science; 2004 Mar; 303(5665):1813-8. PubMed ID: 15031495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of constitutive G protein-coupled receptor activity for drug discovery.
    Chen G; Way J; Armour S; Watson C; Queen K; Jayawickreme CK; Chen WJ; Kenakin T
    Mol Pharmacol; 2000 Jan; 57(1):125-34. PubMed ID: 10617687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural genomics and drug discovery: all in the family.
    Weigelt J; McBroom-Cerajewski LD; Schapira M; Zhao Y; Arrowsmith CH
    Curr Opin Chem Biol; 2008 Feb; 12(1):32-9. PubMed ID: 18282486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand screening system using fusion proteins of G protein-coupled receptors with G protein alpha subunits.
    Suga H; Haga T
    Neurochem Int; 2007; 51(2-4):140-64. PubMed ID: 17659814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.